Holen Sie sich die Stockscreener-App
32.00
5.26%
1.60
Schlusskurs vom Vortag:
$30.40
Offen:
$30.41
24-Stunden-Volumen:
3.26M
Relative Volume:
4.81
Marktkapitalisierung:
$1.99B
Einnahmen:
$32.08M
Nettoeinkommen (Verlust:
$-169.77M
KGV:
-11.26
EPS:
-2.8418
Netto-Cashflow:
$-147.70M
1W Leistung:
+3.23%
1M Leistung:
+3.13%
6M Leistung:
+0.25%
1J Leistung:
+170.27%
1-Tages-Spanne:
$30.39
$32.58
1-Wochen-Bereich:
$30.07
$32.58
52-Wochen-Spanne:
$11.19
$40.22
Stoke Therapeutics Inc Stock (STOK) Company Profile
Firmenname
Stoke Therapeutics Inc
Sektor
Branche
Telefon
781-430-8200
Adresse
45 WIGGINS AVENUE, BEDFORD, MA
Compare STOK vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
STOK
Stoke Therapeutics Inc
|
32.00 | 1.99B | 32.08M | -169.77M | -147.70M | -2.8418 |
VRTX
Vertex Pharmaceuticals Inc
|
491.34 | 124.70B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
632.90 | 66.35B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
887.18 | 55.17B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
291.37 | 38.90B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
182.08 | 38.71B | 742.00K | -1.37B | -1.07B | -7.0731 |
Stoke Therapeutics Inc Stock (STOK) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-02-24 | Eingeleitet | Wolfe Research | Outperform |
| 2026-02-05 | Eingeleitet | Guggenheim | Buy |
| 2026-01-05 | Fortgesetzt | Chardan Capital Markets | Buy |
| 2025-07-18 | Eingeleitet | Jefferies | Buy |
| 2024-12-20 | Eingeleitet | Chardan Capital Markets | Buy |
| 2024-10-14 | Fortgesetzt | Leerink Partners | Outperform |
| 2024-03-26 | Hochstufung | TD Cowen | Market Perform → Outperform |
| 2023-11-20 | Fortgesetzt | JP Morgan | Neutral |
| 2023-07-25 | Herabstufung | TD Cowen | Outperform → Market Perform |
| 2023-05-01 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2023-04-26 | Fortgesetzt | Canaccord Genuity | Buy |
| 2023-01-06 | Herabstufung | BofA Securities | Buy → Underperform |
| 2022-10-24 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2022-01-31 | Eingeleitet | Jefferies | Buy |
| 2021-12-03 | Eingeleitet | BofA Securities | Buy |
| 2021-11-22 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2021-05-18 | Eingeleitet | UBS | Neutral |
| 2021-05-10 | Hochstufung | Wedbush | Neutral → Outperform |
| 2021-04-26 | Fortgesetzt | Credit Suisse | Outperform |
| 2021-02-10 | Herabstufung | Wedbush | Outperform → Neutral |
| 2020-12-15 | Fortgesetzt | H.C. Wainwright | Buy |
| 2020-12-11 | Bestätigt | Needham | Buy |
| 2020-10-23 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2020-09-29 | Fortgesetzt | JP Morgan | Neutral |
| 2020-09-29 | Eingeleitet | Needham | Buy |
| 2019-12-18 | Eingeleitet | Wedbush | Outperform |
| 2019-11-12 | Eingeleitet | BTIG Research | Buy |
| 2019-10-25 | Eingeleitet | H.C. Wainwright | Buy |
| 2019-07-15 | Eingeleitet | Canaccord Genuity | Buy |
| 2019-07-15 | Eingeleitet | Cowen | Outperform |
| 2019-07-15 | Eingeleitet | Credit Suisse | Outperform |
| 2019-07-15 | Eingeleitet | JP Morgan | Overweight |
Alle ansehen
Stoke Therapeutics Inc Aktie (STOK) Neueste Nachrichten
Assenagon Asset Management S.A. Sells 320,708 Shares of Stoke Therapeutics, Inc. $STOK - MarketBeat
Stoke Therapeutics Inc (STOK) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Price to sales forward of Stoke Therapeutics, Inc. – NASDAQ:STOK - TradingView
STOK Forecast — Price Target — Prediction for 2027 - TradingView
0GT Forecast — Price Target — Prediction for 2027 - TradingView
Enterprise value to revenue forward of Stoke Therapeutics, Inc. – NASDAQ:STOK - TradingView
Enterprise value to revenue forward of Stoke Therapeutics, Inc. – GETTEX:0GT - TradingView
Enterprise value to EBITDA forward of Stoke Therapeutics, Inc. – GETTEX:0GT - TradingView
Price to book forward of Stoke Therapeutics, Inc. – NASDAQ:STOK - TradingView
Stoke Therapeutics Inc (STOK) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Price to earnings forward of Stoke Therapeutics, Inc. – NASDAQ:STOK - TradingView
Stoke Therapeutics (STOK) Guggenheim Securities Emerging Outlook: Biotech Summit 2026 summary - Quartr
Stoke Therapeutics StockLong-term strategy and genetic medicine pipeline - Ad-hoc-news.de
Understanding the Setup: (STOK) and Scalable Risk - Stock Traders Daily
Stoke Therapeutics general counsel sells $43,637 in common stock By Investing.com - Investing.com Australia
Stoke Therapeutics general counsel sells $43,637 in common stock - Investing.com UK
Insider Sell Alert: Jonathan Allan Sells Shares of Stoke Therape - GuruFocus
Stoke Therapeutics (STOK) legal chief sells 1,457 shares under 10b5-1 plan - Stock Titan
Stoke Therapeutics Inc (STOK) Institutional Confidence - TradingKey
Stoke Therapeutics Inc (STOK) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Stoke Therapeutics Inc (STOK) Valuation: PE, PB & Fair Value Analysis - TradingKey
Stoke Therapeutics Inc (STOK) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Stoke Therapeutics Inc (STOK) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Stoke Therapeutics Inc (STOK) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Stoke Therapeutics Inc (STOK) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Granahan Investment Management LLC Has $6.08 Million Stock Position in Stoke Therapeutics, Inc. $STOK - MarketBeat
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)June 16, 2026 - BioSpace
Insider sales at STOK (NASDAQ: STOK) list 27,481 shares in March 2026 - Stock Titan
Stoke Therapeutics Stock (US86150R1023): Analyst Sentiment and Valuation Come Into Focus - Ad-hoc-news.de
Stoke Therapeutics, Inc. (NASDAQ:STOK) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Rhenman & Partners Asset Management AB Lowers Position in Stoke Therapeutics, Inc. $STOK - MarketBeat
Stoke Therapeutics (NASDAQ:STOK) Trading Up 1.6%Should You Buy? - MarketBeat
STOK: Durable efficacy and cognitive gains position zorevunersen for a focused U.S. launch by 2028 - TradingView
Stoke Therapeutics (STOK) Goldman Sachs 47th Annual Global Healthcare Conference 2026 summary - Quartr
The Technical Signals Behind (STOK) That Institutions Follow - Stock Traders Daily
Stoke Therapeutics (STOK) director receives grant of 17,786 stock options - Stock Titan
[Form 4] Stoke Therapeutics, Inc. Insider Trading Activity - Stock Titan
Stoke Therapeutics (STOK) director granted 17,786 stock options at $29.46 - Stock Titan
Stoke Therapeutics (STOK) director awarded 17,786 options at $29.46 strike - Stock Titan
Stoke Therapeutics (STOK) director granted options to buy 17,786 shares - Stock Titan
Stoke Therapeutics (STOK) director receives grant of 17,786 stock options at $29.46 - Stock Titan
Stoke Therapeutics (STOK) forms 'hammer chart pattern': Time for bottom fishing? - MSN
Stoke Therapeutics (STOK) Gets a Buy from Leerink Partners - The Globe and Mail
Stoke Therapeutics Stockholders Approve Directors and Governance Items - TipRanks
Stoke Therapeutics (NASDAQ: STOK) 2026 meeting elects all directors - Stock Titan
STOK: Lead therapy delivers durable seizure and cognitive benefits, with pivotal data due mid-2027 - TradingView
Stoke Therapeutics (STOK) Forms 'Hammer Chart Pattern': Time for Bottom Fishing? - Yahoo Finance
Insider Sell Alert: Barry Ticho Sells Shares of Stoke Therapeutics Inc (STOK) - GuruFocus
Insider Sell Alert: Barry Ticho Sells Shares of Stoke Therapeuti - GuruFocus
Stoke Therapeutics (STOK) CMO sells 1,795 shares under 10b5-1 plan - Stock Titan
Stoke Therapeutics Inc Annual Shareholders Meeting Transcript - GuruFocus
Finanzdaten der Stoke Therapeutics Inc-Aktie (STOK)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.36%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):